Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease

DSpace/Manakin Repository

español português english

Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease

Show full item record

Title: Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease
Author: Pineda Marcos, Carmen María; Aguilera Tejero, Escolastico; Morales, María C.; Belinchón Lorenzo, Silvia; Gómez Nieto, Luis Carlos; García López, Pablo; Martínez Moreno, Julio Manuel; Rodríguez Ortiz, María Encarnación; Lopez Villalba, Ignacio
Abstract: El tratamiento de la leishmaniasis canina (CanL) representa un desafío. Debido a la alta prevalencia de enfermedad renal asociada a CanL, es importante encontrar un medicamento eficaz que no dañe los riñones. Se ha demostrado que la marbofloxacina es eficaz y bien tolerada en perros no azotémicos con leishmaniasis. Para evaluar la seguridad y eficacia de la marbofloxacina en perros con leishmaniasis y disminución de la función renal, 28 perros con leishmaniasis y enfermedad renal crónica (ERC) fueron tratados con marbofloxacina oral a 2 mg / kg / día durante 28 días. Durante el tratamiento, los perros se evaluaron realizando exámenes físicos semanales, midiendo la presión arterial y evaluando los parámetros de sangre y orina. También se obtuvieron aspiraciones de ganglios linfáticos en los días 0 y 28. La puntuación clínica global disminuyó significativamente, de 6.2 ± 3.4 a 4.7 ± 3.1 (p = 0.0001), después del tratamiento. La marbofloxacina también disminuyó la carga parasitaria en el 72% de los perros. No se detectaron diferencias significativas en la creatinina plasmática, la gravedad específica de la orina, las concentraciones urinarias de cistatina C, la ferritina y la pérdida de proteínas en la orina durante el tratamiento. Se detectó una disminución transitoria pero significativa de la presión arterial hasta el día 14 (de 180.1 ± 36.6 a 166.0 ± 32.7 mmHg; p = 0.016). Además, los perros mostraron un aumento significativo en la concentración de albúmina en plasma (de 15.0 ± 5.2 a 16.6 ± 3.9 g / L; p = 0.014) y una disminución significativa en la concentración de globulina (de 59.0 ± 18.1 a 54.1 ± 18.0 g / L; p = 0.005). Los resultados demuestran que, además de ser eficaz para el tratamiento de CanL, la marbofloxacina es un fármaco muy seguro en perros con CKD y leishmaniasis.Treatment of canine leishmaniasis (CanL) represents a challenge. Due to the high prevalence of renal disease associated to CanL, it is important to find an effective drug that does not damage the kidneys. Marbofloxacin has been shown to be effective and well tolerated in non-azotemic dogs with leishmaniasis. To evaluate the safety and efficacy of marbofloxacin in dogs with leishmaniasis and decreased renal function, 28 dogs suffering from leishmaniasis and chronic kidney disease (CKD) were treated with oral marbofloxacin at 2 mg/Kg/day for 28 days. During treatment dogs were assessed by performing weekly physical exams, measuring blood pressure and evaluating blood and urine parameters. Lymph node aspirations were also obtained at days 0 and 28. The global clinical score decreased significantly, from 6.2±3.4 to 4.7±3.1 (p = 0.0001), after treatment. Marbofloxacin also decreased parasitic load in 72% of the dogs. No significant differences in plasma creatinine, urine specific gravity, urinary concentrations of cystatin C, ferritin and urinary protein loss were detected during treatment. A transient but significant decrease in blood pressure was detected up to day 14 (from 180.1±36.6 to 166.0±32.7 mmHg; p = 0.016). Moreover, dogs showed a significant increase in plasma albumin concentration (from 15.0±5.2 to 16.6±3.9 g/L; p = 0.014) and a significant decrease in globulin concentration (from 59.0±18.1 to 54.1±18.0 g/L; p = 0.005). The results demonstrate that, in addition to being effective for treatment of CanL, marbofloxacin is a very safe drug in dogs with CKD and leishmaniasis.
URI: http://hdl.handle.net/10662/9017
Date: 2017


Files in this item

Files Size Format View
journal_pone_0185981.pdf 2.735Mb PDF View  Thumbnail

The following license files are associated with this item:

This item appears in the following Collection(s)

Show full item record

Attribution 4.0 International Except where otherwise noted, this item's license is described as Attribution 4.0 International

Search DSpace


Browse

My Account

Statistics

Help

Redes sociales